Business Wire

IQM-QUANTUM-COMPUTERS

12.11.2021 11:02:06 CET | Business Wire | Press release

Share
IQM Quantum Computers Opens a New Fabrication Facility in Finland

As part of its long-term growth strategy, IQM Quantum Computers announces the operation of its new state-of-the-art fabrication and cryogenic characterization facility, which will expand its quantum processor production capacity. This new facility is situated close to its headquarters and quantum labs in Espoo, Finland and marks the company’s largest investment to date.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211112005477/en/

Today, IQM has started its pilot line and will expand with further fabrication lines in the future. These facilities will substantially accelerate the company’s quantum processor design cycle and increase its microelectronics fabrication capacity to keep pace with the dramatic technology shifts underway within national quantum programs, high-performance computing centers, and increasing demand from the industrial customers. In addition, the facilities will ensure the highest industry-level quality required for quantum computing.

“We continue to see increasing demand for our on-premises quantum computers across Europe and globally. Today, we are announcing our largest-ever investment in production to dramatically increase our quantum processor supply and build quantum computers of the future,” said Dr. Jan Goetz, CEO and co-founder of IQM Quantum Computers.

“This investment in equipment, infrastructure and our workforce increases our fabrication, new material research, 3D integration and product delivery capabilities. Today, we’ve started the first phase of our fabrication facility and we plan to continuously learn, and invest in further expansion.”

The pilot line at this facility will be ramped-up over the coming months, and it is expected to reach maximum production capacity during 2022.

This new facility will create high-tech job opportunities and serve as an advanced manufacturing workforce-development initiative. IQM plans to partner with the Finnish and European ecosystems and prepare its workforce for the long-term, high-quality employment and growth opportunities the new facilities will present.

This is another strategic step to strengthen IQM’s position as the category leader for on-premises quantum computers in Europe and provides a strong competitive advantage over other quantum startups.

Facts:

  • Location: Espoo, Finland
  • Investment: € 20 Million
  • Area: 560 m2

About IQM Quantum Computers:

IQM is the Pan-European category leader in building quantum computers.

IQM delivers on-premises quantum computers for supercomputing centers and research laboratories and provides complete access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique, application-specific, co-design approach.

IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium was awarded a project to commercialize application-specific quantum processors by the German Ministry of Education and Research in February 2021.

IQM has raised €71 million from private and public funding and has offices in Espoo, Finland; Munich, Germany; and Bilbao, Spain.

For more information, visit www.meetiqm.com .

Registered office:

IQM Finland Oy
Keilaranta 19
02150 Espoo
Finland
www.meetiqm.com

You can watch the complete recording of the launch event here: https://youtu.be/EUvAfl7a0Vs

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye